Development and clinical application of a primary cancer organoid-PBMC co-culture system for personalized immunotherapy
Drug Resistance Updates · 2026-09 · 88 · 101442
DOI: 10.1016/j.drup.2026.101442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Xueping Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangdon…. Hauptthemen laut MEDLINE: Organoids, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Provincial Natural Science Foundation, Guangzhou Municipal Science and Technology Program key projects, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
AIM: Many patients with non-small cell lung cancer (NSCLC) do not derive clinical benefit from immune checkpoint inhibitors (ICIs), and a reliable method for identifying potential responders is lacking. This study aims to establish an optimized patient-derived organoids (PDOs) culture system and develop a novel organoid-peripheral blood mononuclear cell (PBMC) co-culture platform to evaluate response to ICIs. METHODS: We optimized culture conditions for patient-derived NSCLC organoids by integrating conditional reprogramming techniques. ICIs response was assessed with an organoid-PBMC co-culture system. The accuracy of this ex vivo system was validated by comparing its results with efficacy of ICI therapy in both an in vivo humanized mouse xenograft model and the corresponding patient's clinical response. Moreover, the genomic stability of the organoids during serial passaging was monitored through gene sequencing. RESULTS: An optimal indirect co-culture system was established, culturing organoids with 25% Matrigel. This system consisted of 40 Gy-irradiated Swiss 3T3-J2 fibroblasts in an upper chamber and primary NSCLC cells in a lower chamber, using F-medium (DMEM/F-12 (3:1, v/v) + 10 µM Y-27632) supplemented with 0.5 µM A83-01. This method achieved an 85.59% (95/111) success rate. Using this platform, we evaluated PD-1 antibody efficacy with the organoid-PBMC co-culture system in 70 cases. For in vivo validation, a direct patient-derived organoid xenograft (PDOX) models were established in humanized mice reconstituted with the corresponding patient's PBMCs. Notably, the ex vivo results demonstrated a strong correlation with both the in vivo validation data and patients' actual clinical responses to ICIs, yielding a sensitivity of 100% and a specificity of 62.20%. CONCLUSION: We developed a novel, simple, rapid and reliable organoid-PBMC co-culture system for screening the response of NSCLC patients to ICI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen Universi…
- Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 999077, Hong Kong, China.
Förderung
- Guangdong Provincial Natural Science Foundation
- Guangzhou Municipal Science and Technology Program key projects
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
- Special Project for Research and Development in Key areas of Guangdong Province
- Sun Yat-sen University Cancer Center
- National Key Research and Development Program of China
- State Key Laboratory of Oncology in South China
Zitieren
APA
Wang, X., Li, J., Wu, X., Pan, C., Luo, M., Fu, K., Li, S., Zhu, S., Lan, Y., Fan, Y., To, K. K. W., Wang, F., & Fu, L. (2026). Development and clinical application of a primary cancer organoid-PBMC co-culture system for personalized immunotherapy. Drug Resistance Updates, 88, 101442. https://doi.org/10.1016/j.drup.2026.101442
Vancouver
Wang X, Li J, Wu X, Pan C, Luo M, Fu K, et al. Development and clinical application of a primary cancer organoid-PBMC co-culture system for personalized immunotherapy. Drug Resistance Updates. 2026;88:101442. doi:10.1016/j.drup.2026.101442
BibTeX
@article{Wang2026,
author = {Wang, Xueping and Li, Jinsui and Wu, Xingping and Pan, Can and Luo, Min and Fu, Kai and Li, Sijia and Zhu, Shuangli and Lan, Yuelu and Fan, Yingfang and To, Kenneth K W and Wang, Fang and Fu, Liwu},
title = {Development and clinical application of a primary cancer organoid-PBMC co-culture system for personalized immunotherapy},
journal = {Drug Resistance Updates},
year = {2026},
volume = {88},
pages = {101442},
doi = {10.1016/j.drup.2026.101442}
}
EUVIMED